Skip to main content
. 2022 Jun 16;8(8):1160–1168. doi: 10.1001/jamaoncol.2022.1981

Table 2. Objective Response Rate, Progression-Free, and Overall Survival to PD-1/PD-L1 Blockade in High and Low TMB Non–Small Cell Lung Cancer According to PD-L1 Expression Subgroups.

Outcome and PD-L1 tumor proportion score Low TMB High TMB P value
Objective response rate, % (95% CI)
<1% 8.7 (5.5-12.9) 46.7 (28.3-65.7) <.001
1%-49% 18.7 (14.1-23.9) 50.0 (31.3-68.7) <.001
≥50% 38.1 (33.3-43.0) 56.5 (41.1-71.1) .02
Progression-free survival, median (95% CI), mo
<1% 2.1 (2.0-2.4) 10.7 (8.2-24.4) <.001
1%-49% 2.9 (2.5-3.6) 13.6 (8.6-NR) <.001
≥50% 5.2 (4.6-6.2) 18.1 (8.6-NR) <.001
Overall survival, median (95% CI), mo
<1% 10.4 (7.9-13.6) 23.9 (16.7-NR) .07
1%-49% 11.3 (9.6-14.7) NR (21.2-NR) <.001
≥50% 21.4 (17.5-25.9) 47.7 (35.4-NR) .02

Abbreviations: NR, not reached; PD-1, programmed cell death–1; PD-L1, programmed death ligand–1; TMB, tumor mutation burden.